Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Share this content:
Binimetinib a BRAF inhibitor, improved objective response rate and progression-free survival among patients with BRAF-mutant melanoma.
Binimetinib a BRAF inhibitor, improved objective response rate and progression-free survival among patients with BRAF-mutant melanoma.
The following article features coverage from the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. Click here to read more of Cancer Therapy Advisor's conference coverage.

Binimetinib, a MEK inhibitor, plus encorafenib, a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma, which confirmed earlier findings with a higher encorafenib dose, according to research presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Spain.1

Binimetinib (45 mg twice daily) plus encorafenib (400 mg once daily) improved PFS compared with vemurafenib or encorafenib (300 mg once daily) alone in part 1 of the phase 3 COLUMBUS trial. Part 2 of the trial sought to determine if this benefit was maintained at the control dose of encorafenib 300 mg.1

In part 2 of the COLUMBUS trial, patients with metastatic melanoma that harbored the BRAF V600 mutation were randomly assigned 3:1 to receive binimetinib (45 mg twice daily) plus encorafenib (300 mg once daily) or encorafenib (300 mg once daily) alone. Analysis of the encorafenib arm included data from the encorafenib arm from part 1 of the trial.

The ORR with the combination was 66% compared with 50% and 50% with encorafenib alone in the pooled data and part 2 arm only, respectively.

PFS was prolonged with the binimetinib and encorafenib combination, with a median of 12.9 months (95% CI, 10.1-14.0 months) compared with 9.2 months (95% CI, 7.4-11.0 months) from the encorafenib pooled data (hazard ratio [HR], 0.77; 95% CI, 0.61-0.97; P = .029) and 7.4 months (95 % CI, 5.6-9.2) in the encorafenib arm from part 2 only (HR, 0.57; 95% CI, 0.41-0.78; P < .001).

Discontinuation of the study due to adverse events (AEs) was similar among arms (10% to 12%), though more patients required dose modification due to AEs with encorafenib alone (69% pooled data and 63% part 2 only) compared with the combination (45%).

AEs that occurred less frequently with the combination compared with encorafenib alone included nausea, arthralgia, vomiting, myalgia, alopecia, headache, and extremity pain.

RELATED: Knowledge of Immunotherapies in Melanoma Continues to Grow

According to the investigators, results from part 2 of the COLUMBUS trial confirm the benefit of the addition of binimetinib to encorafenib in terms of efficacy and safety.

Read more of Cancer Therapy Advisor's coverage of the European Society of Medical Oncology (ESMO) 2017 Congress by visiting the conference page.

Reference

  1. Dummer R, Ascierto PA, Gogas H, et al. Results of COLUMBUS Part 2: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Presented at: ESMO 2017 Congress; Madrid, Spain: September 8-12, 2017. Abstract 1215O.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs